United Therapeutics (UTHR) Raw Materials (2010 - 2020)

United Therapeutics has disclosed Raw Materials across 11 years of filings, most recently posting $20.1 million for Q1 2020.

• Raw Materials for Q1 2020 came in at $20.1 million, down 9.87% year-over-year; the trailing twelve-month figure through Mar 2020 was $20.1 million (down 9.87% YoY), and the FY2019 annual result was $21.1 million, down 13.17% from the prior year.
• Raw Materials came in at $20.1 million for Q1 2020 at United Therapeutics, down from $21.1 million in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $29.1 million in Q2 2017 to a low of $19.3 million in Q3 2019.
• The 5-year median for Raw Materials is $24.8 million (2016), against an average of $24.4 million.
• Across the five-year window, Raw Materials climbed 17.34% in 2017 and declined 25.77% in 2019, its largest moves.
• United Therapeutics' Raw Materials stood at $25.4 million in 2016, then increased by 9.84% to $27.9 million in 2017, then fell by 12.9% to $24.3 million in 2018, then slipped by 13.17% to $21.1 million in 2019, then retreated by 4.74% to $20.1 million in 2020.
• The last three Raw Materials figures came in at $20.1 million (Q1 2020), $21.1 million (Q4 2019), and $19.3 million (Q3 2019), per Business Quant data.